WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Dr. P. Mekala*, Dr. A. Jagadeeswaran, Dr. A. Arivuchelvan, Dr. P. Senthil Kumar,
Dr. K. Nanjappan and Dr. T. R. Gopala Krishna Murthy


The study was conducted to explore the influence of hydrated sodium calcium aluminosilicate (HSCAS), a toxin binder commonly used in poultry feed, on the pharmacokinetic behavior of enrofloxacin in broiler chicken. Control group received normal feed free of toxin binder whereas HSCAS group was supplemented with HSCAS @ 0.5% in feed. Enrofloxacin was administered as single pulse dose (@10mg.kg-1) through drinking water to both the groups. Blood samples were collected at predetermined time intervals after drug administration and plasma was separated and analyzed for enrofloxacin concentrations using HPLC. Highly significant (p<0.01) decrease in mean plasma concentration of enrofloxacin was noticed in HSCAS group at 4 and 6h which was preceded (2h) by significant (p<0.05) decrease when compared to control group. The Cmax of HSCAS group was significantly (p<0.01) lower than the control group (0.97±0.06 vs 1.38±0.04μg.mL-1). Tmax was significantly (p<0.05) delayed in HSCAS group (6.670.67 vs 4.330.67h) when compared to control group. Highly significant increase in Vd ss/F (9.340.48 vs 7.210.20L.kg-1) was noticed in HSCAS group when compared to control group. Relative bioavailability of HSCAS group was calculated to be 88.88±15.03% by treating the bioavailability of control group as 100%. The other pharmacokinetic parameters did not differ significantly though there were numerical differences. Integration of PK/PD parameters revealed that the dose of enrofloxacin (10mg.kg-1) was sufficient to treat only moderately sensitive organisms (MIC≤0.125μg.mL-1) both in the presence and absence of toxin binder and increase in dosage is needed to treat less sensitive organisms. Hence it is suggested to either increase the dosage of enrofloxacin or withdraw the feed containing HSCAS during enrofloxacin treatment in broiler chicken in order to prevent the emergence of resistance as well as to obtain clinical cure.

Keywords: Pharmacokinetics, Enrofloxacin, HSCAS, Toxin binder, Pulse dosing, HPLC.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More